Marinus Pharmaceuticals Inc (NASDAQ: MRNS) closed the day trading at $8.70 down -1.92% from the previous closing price of $8.87. In other words, the price has decreased by -$0.17 from its previous closing price. On the day, 799759 shares were traded.
Ratios:
For a better understanding of MRNS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.01 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 6.58 whereas as Long-Term Debt/Eq ratio is at 5.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Oppenheimer on August 11, 2023, Downgraded its rating to Perform and sets its target price to $9 from $14 previously.
On January 20, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $23.
On September 30, 2020, Truist started tracking the stock assigning a Buy rating and target price of $35.Truist initiated its Buy rating on September 30, 2020, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 20 ’24 when Shafer Christina sold 2,153 shares for $9.56 per share. The transaction valued at 20,583 led to the insider holds 60,308 shares of the business.
MANNING MARTHA E sold 1,894 shares of MRNS for $18,126 on Feb 20 ’24. The SVP, GEN. COUNSEL & CORP. SEC. now owns 52,966 shares after completing the transaction at $9.57 per share. On Feb 16 ’24, another insider, Braunstein Scott, who serves as the CHAIRMAN AND CEO of the company, sold 11,850 shares for $9.94 each. As a result, the insider received 117,789 and left with 223,512 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNS now has a Market Capitalization of 484.68M and an Enterprise Value of 408.14M. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.34 while its Price-to-Book (P/B) ratio in mrq is 28.32. Its current Enterprise Value per Revenue stands at 13.17 whereas that against EBITDA is -3.25.
Stock Price History:
The Beta on a monthly basis for MRNS is 0.89, which has changed by 32.02% over the last 52 weeks, in comparison to a change of 26.95% over the same period for the S&P500. Over the past 52 weeks, MRNS has reached a high of $11.26, while it has fallen to a 52-week low of $5.57. The 50-Day Moving Average of the stock is 9.52, while the 200-Day Moving Average is calculated to be 8.59.
Shares Statistics:
Over the past 3-months, MRNS traded about 433.33K shares per day on average, while over the past 10 days, MRNS traded about 489.19k shares per day. A total of 54.58M shares are outstanding, with a floating share count of 50.81M. Insiders hold about 7.01% of the company’s shares, while institutions hold 94.03% stake in the company. Shares short for MRNS as of Mar 15, 2024 were 3.57M with a Short Ratio of 8.25, compared to 3.57M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.54% and a Short% of Float of 6.59%.
Earnings Estimates
Current recommendations for the stock of the company come from 10 analysts. On average, analysts expect EPS of -$0.63 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$0.69, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$0.58, with high estimates of -$0.52 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$2.06 and -$2.98 for the fiscal current year, implying an average EPS of -$2.36. EPS for the following year is -$1.87, with 11 analysts recommending between -$1.29 and -$2.6.
Revenue Estimates
11 analysts predict $9.09M in revenue for the current quarter. It ranges from a high estimate of $15.02M to a low estimate of $6.25M. As of the current estimate, Marinus Pharmaceuticals Inc’s year-ago sales were $10.38M, an estimated decrease of -12.40% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $9.25M, an increase of 52.10% over than the figure of -$12.40% in the same quarter last year. There is a high estimate of $11.8M for the next quarter, whereas the lowest estimate is $6.1M.
A total of 11 analysts have provided revenue estimates for MRNS’s current fiscal year. The highest revenue estimate was $54.3M, while the lowest revenue estimate was $33.22M, resulting in an average revenue estimate of $40.53M. In the same quarter a year ago, actual revenue was $30.99M, up 30.80% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $66.62M in the next fiscal year. The high estimate is $127.7M and the low estimate is $42.5M. The average revenue growth estimate for next year is up 64.40% from the average revenue estimate for this year.
